Hypermethylation of CDH13, DKK3 and FOXL2 promoters and the expression of EZH2 in ovary granulosa cell tumors

Molecular Medicine Reports

Volumn 14, Issue 3, 2016, Pages 2739-2745

  Xu, Yanmei ^a,b   Li, Xia ^c   Wang, Hongtao ^d   Xie, Pengmu ^b   Yan, Xun ^b   Bai, Yu ^b   Zhang, Tingguo ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shandong Shanxian Central Hospital   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathological features; DNA methylation; Granulosa cell tumors; Histone modifications; Tumor suppressor gene

Indexed keywords

TRANSCRIPTION FACTOR EZH2; BIOLOGICAL MARKER; CADHERIN; DKK3 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXL2 PROTEIN, HUMAN; H-CADHERIN; SIGNAL PEPTIDE;

ADULT; ARTICLE; CADHERIN 13 GENE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DICKKOPF WNT SIGNALING PATHWAY INHIBITOR 3 GENE; FEMALE; FORKHEAD BOX L2 GENE; GENE; GRANULOSA CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; TUMOR VOLUME; WNT SIGNALING PATHWAY; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; YOUNG ADULT;

ADULT; BIOMARKERS; CADHERINS; DNA METHYLATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EPIGENESIS, GENETIC; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GRANULOSA CELL TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; RECURRENCE; TUMOR BURDEN; YOUNG ADULT;

EID: 84989182787     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5521     Document Type: Article

References (60)

1. Sun HD, Lin H, Jao MS, Wang KL, Liou WS, Hung YC, Chiang YC, Lu CH, Lai HC and Yu MH: A long-term follow-up study of 176 cases with adult-type ovarian granulosa cell tumors. Gynecol Oncol 124: 244-249, 2012
2. Lee YK, Park NH, Kim JW, Song YS, Kang SB and Lee HP: Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer 18: 642-647, 2008
3. Hashem IAT, Yaqoob I, Anuar NB, Mokhtar S, Gani A and Ullah Khan S: The rise of 'big data' on cloud computing: Review and open research issues. Inform Syst 47: 98-115, 2015
4. Gomes A, Reis-Silva M, Alarcão A, Couceiro P, Sousa V and Carvalho L: Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung. Rev Port Pneumol 20: 20-30, 2014
5. Amente S, Lania L and Majello B: Epigenetic reprogramming of Myc target genes. Am J Cancer Res 1: 413-418, 2011
6. Nishida N, Kudo M, Nagasaka T, Ikai I and Goel A: Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 56: 994-1003, 2012
7. Ling Q, Shi W, Huang C, Zheng J, Cheng Q, Yu K, Chen S, Zhang H, Li N and Chen M: Epigenetic silencing of dual oxidase 1 by promoter hypermethylation in human hepatocellular carcinoma. Am J Cancer Res 4: 508-517, 2014
8. Sun D, Zhang Z, Van Do N, Huang G, Ernberg I and Hu L: Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral Oncol 43: 82-87, 2007
9. Kim JS, Han J, Shim YM, Park J and Kim DH: Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer 104: 1825-1833, 2005
10. Putku M, Kals M, Inno R, Kasela S, Org E, Koẑich V, Milani L and Laan M: CDH13 promoter SNPs with pleiotropic effect on cardiometabolic parameters represent methylation QTLs. Hum Genet 134: 291-303, 2015
11. Yoo KH and Hennighausen L: EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 8: 59-65, 2012
12. Kontic M, Stojsic J, Jovanovic D, Bunjevacki V, Ognjanovic S, Kuriger J, Puumala S and Nelson HH: Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma. Clin Lung Cancer 13: 297-303, 2012
13. Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knüchel R and Dahl E: Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res 15: R4, 2013
14. Zhou XY, Sun JF, He YH, Zhang HY, Yu J, Guo SC, Cai Y, Hu XC and Zhu JD: Correlation of the methylation status of CpG islands in the promoter region of 10 genes with the 5-Fu chemosensitivity in 3 breast cancer cell lines. Zhonghua Zhong Liu Za Zhi 32: 328-333, 2010
15. Friedrichs K, Gluba S, Eidtmann H and Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641-3647, 1993
16. Dhillon VS, Young AR, Husain SA and Aslam M: Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin. Br J Cancer 90: 874-881, 2004
17. Chen H, Zhang C, Sheng Y, Yao S, Liu Z, Zhang C and Zhang T: Frequent SOCS3 and 3OST2 promoter methylation and their epigenetic regulation in endometrial carcinoma. Am J Cancer Res 5: 180-190, 2014
18. Dhillon VS, Aslam M and Husain SA: The contribution of genetic and epigenetic changes in granulosa cell tumors of ovarian origin. Clin Cancer Res 10: 5537-5545, 2004
19. Dhillon VS, Shahid M and Husain SA: CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer 3: 33, 2004
20. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD and Gazdar AF: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 61: 4556-4560, 2001
21. Toyooka S, Toyooka KO, Harada K, Miyajima K, Makarla P, Sathyanarayana UG, Yin J, Sato F, Shivapurkar N, Meltzer SJ and Gazdar AF: Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res 62: 3382-3386, 2002
22. Xu J, Shetty PB, Feng W, Chenault C, Bast RC Jr, Issa JP, Hilsenbeck SG and Yu Y: Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 12: 243, 2012
23. Zhai X and Li SJ: Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer. Asian Pac J Cancer Prev 15: 4925-4928, 2014
24. Zhai X and Li SJ: Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer. Asian Pac J Cancer Prev 15: 4925-4928, 2014
25. Zhong YH, Peng H, Cheng HZ and Wang P: Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer. Asian Pac J Cancer Prev 16: 1139-1143, 2015
26. Xue R, Yang C, Zhao F and Li D: Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC. Onco Targets Ther 7: 1987-1996, 2014
27. Hibi K, Kodera Y, Ito K, Akiyama S and Nakao A: Aberrant methylation of HLTF, SOCS-1 and CDH13 genes is shown in colorectal cancers without lymph node metastasis. Dis Colon Rectum 48: 1282-1286, 2005
28. Riou P, Saffroy R, Chenailler C, Franc B, Gentile C, Rubinstein E, Resink T, Debuire B, Piatier-Tonneau D and Lemoine A: Expression of T-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma. FASEB J 20: 2291-2301, 2006
29. Lin YL, Xie PG and Ma JG: Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer. Med Sci Monit 20: 1572-1577, 2014
30. Abudukadeer A, Bakry R, Goebel G, Mutz-Dehbalaie I, Widschwendter A, Bonn GK and Fiegl H: Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients. Int J Mol Sci 13: 8353-8363, 2012
31. Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z and Lind GE: DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer 6: 45, 2007
32. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF and Schorge JO: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11: 5365-5369, 2005
33. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA and Gazdar AF: Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8: 3324-3331, 2002
34. Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI and Shridhar V: Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol 15: 715-720, 1999
35. Yu J, Tao Q, Cheng YY, Lee KY, Ng SS, Cheung KF, Tian L, Rha SY, Neumann U, Röcken C, et al: Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 115: 49-60, 2009
36. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, Chan AT, Sung JJ and Tao Q: WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 14: 55-61, 2008
37. Hayashi T, Asano H, Toyooka S, Tsukuda K, Soh J, Shien T, Taira N, Maki Y, Tanaka N, Doihara H, et al: DNA methylation status of REIC/Dkk-3 gene in human malignancies. J Cancer Res Clin Oncol 138: 799-809, 2012
38. Voorham QJ, Janssen J, Tijssen M, Snellenberg S, Mongera S, van Grieken NC, Grabsch H, Kliment M, Rembacken BJ, Mulder CJ, et al: Promoter methylation of Wnt-antagonists in polypoid and nonpolypoid colorectal adenomas. BMC Cancer 13: 603, 2013
39. Yin DT, Wu W, Li M, Wang QE, Li H, Wang Y, Tang Y and Xing M: DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. Endocr Relat Cancer 20: 507-514, 2013
40. Kang WS, Cho SB, Park JS, Lee MY, Myung SC, Kim WY, Lee SH, Kim DH and Lee EJ: Clinico-epigenetic combination including quantitative methylation value of DKK3 augments survival prediction of the patient with cervical cancer. J Cancer Res Clin Oncol 139: 97-106, 2013
41. Liang L, He H, Lv R, Zhang M, Huang H, An Z and Li S: Preliminary mechanism on the methylation modification of Dkk-1 and Dkk-3 in hepatocellular carcinoma. Tumour Biol 36: 1245-1250, 2015
42. Tao L, Huang G, Chen Y and Chen L: DNA methylation of DKK3 modulates docetaxel chemoresistance in human nonsmall cell lung cancer cell. Cancer Biother Radiopharm 30: 100-106, 2015
43. Ottolenghi C, Omari S, Garcia-Ortiz JE, Uda M, Crisponi L, Forabosco A, Pilia G and Schlessinger D: Foxl2 is required for commitment to ovary differentiation. Hum Mol Genet 14: 2053-2062, 2005
44. Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC and Treier M: The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development 131: 933-942, 2004
45. Rosario R, Araki H, Print CG and Shelling AN: The transcriptional targets of mutant FOXL2 in granulosa cell tumours. PLoS One 7: e46270, 2012
46. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, et al: Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360: 2719-2729, 2009
47. Jamieson S, Butzow R, Andersson N, Alexiadis M, Unkila-Kallio L, Heikinheimo M, Fuller PJ and Anttonen M: The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol 23: 1477-1485, 2010
48. Kim MS, Hur SY, Yoo NJ and Lee SH: Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J Pathol 221: 147-152, 2010
49. D'Angelo E, Mozos A, Nakayama D, Espinosa I, Catasus L, Muñoz J and Prat J: Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod Pathol 24: 1360-1367, 2011
50. Oseto K, Suzumori N, Nishikawa R, Nishikawa H, Arakawa A, Ozaki Y, Asai H, Kawai M, Mizuno K, Takahashi S, et al: Mutational analysis of FOXL2 p.C134W and expression of bone morphogenetic protein 2 in Japanese patients with granulosa cell tumor of ovary. J Obstet Gynaecol Res 40: 1197-1204, 2014
51. Tran S, Wang Y, Lamba P, Zhou X, Boehm U and Bernard DJ: The CpG island in the murine foxl2 proximal promoter is differentially methylated in primary and immortalized cells. PLoS One 8: e76642, 2013
52. Zhao Y, Zhou H, Ma K, Sun J, Feng X, Geng J, Gu J, Wang W, Zhang H, He Y, et al: Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer. Oncol Lett 5: 1211-1218, 2013
53. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010
54. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, et al: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874, 2006
55. Cao R and Zhang Y: The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14: 155-164, 2004
56. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M and Schulz WA: Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 6: 1403-1412, 2007
57. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and Akslen LA: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273, 2006
58. Wang J, Yu L, Cai J, Jia J, Gao Y, Liang M and Wang Z: The role of EZH2 and DNA methylation in hMLH1 silencing in epithelial ovarian cancer. Biochem Biophys Res Commun 433: 470-476, 2013
59. Kodach LL, Jacobs RJ, Heijmans J, van Noesel CJ, Langers AM, Verspaget HW, Hommes DW, Offerhaus GJ, van den Brink GR and Hardwick JC: The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 31: 1567-1575, 2010
60. Rush M, Appanah R, Lee S, Lam LL, Goyal P and Lorincz MC: Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation. Epigenetics 4: 404-414, 2009